NEWS RELEASE

Incubate Bio announces the first Generative AI engine for DNA Damage Repair target discovery – AskMaddy

- *A self-correcting, agent driven, retrieval augmented Large Language Model (LLM) for DNA Damage Repair (DDR)*
- *As an integral part of the ALaSCA Causal AI framework, AskMaddy rapidly extracts literature evidence for identified DDR-related targets*

London, December 7, 2023 – Incubate Bio announces the commercial availability of AskMaddy, the life science industry's first LLM for DNA Damage Repair (DDR) related drug discovery.

Named after Professor Penelope Maddy (https://faculty.sites.uci.edu/pjmaddy/) in recognition of her impact in science and logic, AskMaddy has been developed with the scientist in mind.

Given the complexity of the DDR in oncology, AskMaddy plays a key role in helping researchers get actionable insights while saving hours of time piecing information together. Simpler retrieval augmented generation tools lack the domain expertise needed to answer detailed biological questions, and still often lack sufficient reliability and robustness. AskMaddy's built in QA and evaluation system can compare different base LLMs and system versions, ensuring reliability when changes are made.

AskMaddy has already been applied to Incubate Bio's proprietary pipeline (http://incubate.bio/pipeline), enhancing understanding of the different pathways involved in the DDR and the role they play in cancer.

Within the ALaSCA framework, AskMaddy performs several key functions including:

- Describing the mechanisms of cancer development and subtypes.
- Identifying mechanisms of therapeutic resistance and potential alternative therapeutic combinations.
- Summarizing the function of targets and their potential role in therapeutic resistance.

"AskMaddy is an exciting new tool that enables drug scientists to rapidly interrogate and explore DDR pathways. With AskMaddy, ALaSCA is able to both identify pathways of

resistance and extract critical evidence from literature within a single automated workflow." **Dr Sitta Sittampalam, Senior Advisor to the NIH**, and member of Incubate Bio's Scientific Advisory Board.

This first-of-a-kind Generative AI engine for DDR target discovery is the output of a strategic partnership between Incubate Bio and Ominor AI. The Causal AI and biology expertise from Incubate Bio and the LLM development skills of Ominor have been successfully combined to create AskMaddy.

For more information contact info@incubate.bio

+++ END +++

About Incubate Bio

Incubate Bio is pinpointing and validating the causal links between targets and cancer, using its proprietary ALaSCA technology to inform pipeline decision making. Using pathway analysis to identify key drivers and supports for target discovery and identification - indication expansion & extension (repurposing), possible combination therapies and patent life-cycle management.

With a primary focus on oncology (specifically the DNA Damage Repair, DDR, pathway, synthetic lethality), we are generating unique in silico data packages containing characterised and prioritised targets and biomarkers with critical supporting evidence.

For more about Incubate bio: https://www.incubate.bio/

About Ominor AI

Ominor AI is a premier AI consulting firm, specializing in healthcare, retail, and logistics. The team brings together deep expertise in artificial intelligence, and data science and combines it with management and operational consulting to ensure business impact. Ominor offers comprehensive services including AI strategy development, prototyping, and deployment of cutting-edge AI tools.

For more information: https://www.ominor.ai/